4 ms·
“Yescarta and Kymriah do work similarly, though. Each involves removing a patient's T-cells and shipping them to a facility where they're engineered to spot and
by benmarks 9y ago
“Yescarta and Kymriah do work similarly, though. Each involves removing a patient's T-cells and shipping them to a facility where they're engineered to spot and bind to CD19, a protein commonly expressed by B-cell cancers. Once the companies have finished altering the T-cells, they're infused back into the patient.”
This seems to be quite an outlier in a discussion on general vaccine economics.
- JumpCrisscross 9y agoEDIT: wrong link; replaced.
- mft_ 9y agoThe article you linked to discusses the cost of CAR-T therapies for DLBCL and ALL, not a Hep-C cure. That's what the previous commenter was referring to as 'an outlier'.
- JumpCrisscross 9y agoMy bad—fixed. Thanks for the heads up.